Skip to main content
. 2024 Mar 18;83(6):706–719. doi: 10.1136/ard-2024-225531

Table 1.

Disease-modifying treatment options for psoriatic arthritis in 2023

Type of DMARD Target Name of drug
csDMARD

  • Methotrexate

  • Leflunomide

  • Sulfasalazine
bDMARD TNF

  • Adalimumab

  • Certolizumab

  • Etanercept

  • Infliximab

  • Golimumab
IL-12/23

  • Ustekinumab
IL-17A

  • Ixekizumab

  • Secukinumab
IL-17A/F

  • Bimekizumab
IL-23-p19

  • Guselkumab

  • Risankizumab
CTLA4

  • Abatacept
tsDMARD PDE4

  • Apremilast
JAK

  • Tofacitinib.

  • Upadacitinib.

Drugs currently authorised as of December 2023 for use in psoriatic arthritis.

bDMARD, biological disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DMARD, disease-modifying antirheumatic drug; IL, interleukin; JAK, Janus kinase; PDE4, phosphodiesterase 4; TNF, tumour necrosis factor; tsDMARD, targeted synthetic disease-modifying antirheumatic drug.